VKTX

Viking's ongoing phase 3 trials are the key to unlocking value for shareholders. Its lead drug, VK2735, has demonstrated impressive results in a phase 2 trial.

The weight loss drug market is on track to reach nearly $100 billion by the end of the decade. Viking has a candidate, in two formulations, involved in phase 3 studies.

SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference in November and December. Details of the company's participation are as follows: Stifel 2026 Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 10-12, 2026Fireside Chat Date/Time: Wednesday, November 11th, 10:40 am – 11:10 am ETLocation: New York, NY Truist 2026 BioPharma Symposium Details: Viking management will participate in investor meetings.Conference Date: November 12, 2026Location: New York, NY UBS Global Biopharma Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 16-17, 2026Fireside Chat Date/Time: Tuesday, November 17th, 10:40 am - 11:10 am ETLocation: London, UK Jefferies Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: November 16-19, 2026Fireside Chat Date/Time: Wednesday, November 18th, 2:00 pm – 2:25 pm GMTLocation: London, UKWebcast available Piper Sandler 38th Annual Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings.Conference Dates: December 1-3, 2026Fireside Chat Date/Time: Wednesday, December 2nd, 2:00 pm - 2:25 pm ETLocation: New York, NYWebcast available A live webcast of the Jefferies and Piper Sandler fireside chats may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.

UBS sees approximately 250% upside potential for Viking shares over the next year. Viking's weight loss candidates could compete effectively with the established drugs from Eli Lilly and Novo Nordisk.

Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.

Viking Therapeutics advances its Phase III obesity trials, reports promising VK2735 maintenance data and strengthens its cash position despite widening losses.

Eli Lilly (NYSE:LLY | LLY Price Prediction) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving.

Viking Therapeutics' maintenance data met upside criteria but failed to excite the market, with shares dropping post-release and dilution ongoing. VKTX is clearly pursuing a standalone strategy, ramping OpEx and infrastructure despite formidable competition from Eli Lilly and Novo Nordisk. Viking's multi-modal maintenance strategy—injectable induction followed by oral or monthly maintenance—addresses injection fatigue but faces a race against advancing competitors.